Cannabis company begins trading in the US

Cannabis company begins trading in the US

ZELDA Therapeutics Limited (ASX: ZLD) has increased its international footprint by trading on the US public market as it looks to attract North American investors into the medicinal cannabis company.

Its shares have been approved for trading on the OTCQB Venture Market (OTCQB) in the United States under the trading symbol 'ZLDAF'.

The company says the listing will facilitate greater investor access to the company's activities and significantly expand the pool of investors able to invest in the company.

This dual listing structure is non-dilutive to existing Zelda shareholders, and no capital is being raised and no new shares are being issued.

The OTCQB is a US-based trading platform for early-stage and developing companies.

The platform's quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for US-based investors.

Chairman of Zelda, Harry Karelis, says the listing will allow greater access to the company's potential for international investors.

"As part of our ongoing strategy to introduce Zelda Therapeutics to a broader international audience, this milestone will provide greater visibility, better access to the US investment community, and improved convenience of trading in Zelda's ordinary shares," says Karelis.

"We expect to achieve a number of significant milestones over the course of 2018 that we believe will be of great interest to US-based investors and this listing forms part of an overall investor relations strategy."

In December last year, Zelda marked another milestone by announcing its partnership with the Children's Hospital of Philadelphia to study the effects of medical cannabis treatment in paediatric autism.

As one of Australia's prominent listed medical cannabis companies, Zelda will co-investigate the effects of cannabinoid treatments through an observation trial.

The company says its goal is to understand the effectiveness of cannabinoids, while working closely with patient advocacy groups and licensed cannabis growers.

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

Get our daily business news

Sign up to our free email news updates.

 
Finexia’s Childcare Income Fund secures ‘very strong’ rating from Foresight Analytics & Ratings
Partner Content
Private credit specialist Finexia Financial Group (ASX: FNX) has secured a “very...
Finexia
Advertisement

Related Stories

Don’t understand predictive algorithms? Xplainable bridges the “how and why” gap of machine learning

Don’t understand predictive algorithms? Xplainable bridges the “how and why” gap of machine learning

"There is so much hype around AI. Let's just focus on...

IHG teams with UK venture capitalist Felix for four-star Holiday Inn at Caloundra

IHG teams with UK venture capitalist Felix for four-star Holiday Inn at Caloundra

IHG Hotels & Resorts has partnered with London-based funds mana...

Construction and hospitality dominate insolvencies amid 36pc spike in administrator appointments

Construction and hospitality dominate insolvencies amid 36pc spike in administrator appointments

Whilst barely a fortnight goes by when a well-known Australian comp...

Visa Foundation backs First Australians Capital with $2m investment

Visa Foundation backs First Australians Capital with $2m investment

First Australians Capital's (FAC) Catalytic Capital Impact Fund...